Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer In addition to Merck and Eisai, Bristol Myers Squibb (BMS) also has a new potential advanced RCC treatment in the form of a combination treatment containing its checkpoint inhibitor Opdivo (nivolumab) ... Data presented at the 2020 European Society for

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC In the phase 3 CheckMate-816 trial, Opdivo (nivolumab) was evaluated in combination with chemotherapy in patients with resectable NSCLC before surgery. ... Patients in the experimental arm of the trial received up to three doses of Opdivo plus

Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer

Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer Opdivo is also chasing approval in the first-line setting, with BMS revealing promising data for the PD-1 inhibitor at this treatment stage at ESMO 2020. ... In addition, the median duration of treatment for patients in the Opdivo arm was 10.1 months,

BMS eyes approval for second Opdivo combo in kidney cancer

BMS eyes approval for second Opdivo combo in kidney cancer Detailed results presented at ESMO 2020 virtual congress. Bristol Myers Squibb has reported positive data for a combination of its PD-L1 inhibitor Opdivo with Exelixis’ Cabometyx in renal cell carcinoma ... Opdivo is already approved in combination

Keytruda improves survival in first-line oesophageal cancer

Keytruda improves survival in first-line oesophageal cancer Currently, Bristol Myers Squibb’s rival checkpoint inhibitor Opdivo (nivolumab) is Keytruda’s only potential competitor in oesophageal cancer. ... The survival benefit with Opdivo treatment was observed regardless of PD-L1 expression levels.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics